Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr;118(7):1005-1012.
doi: 10.1038/s41416-018-0007-z. Epub 2018 Mar 9.

Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project

Affiliations

Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project

Jessica L Petrick et al. Br J Cancer. 2018 Apr.

Abstract

Background: While tobacco and alcohol are established risk factors for hepatocellular carcinoma (HCC), the most common type of primary liver cancer, it is unknown whether they also increase the risk of intrahepatic cholangiocarcinoma (ICC). Thus, we examined the association between tobacco and alcohol use by primary liver cancer type.

Methods: The Liver Cancer Pooling Project is a consortium of 14 US-based prospective cohort studies that includes data from 1,518,741 individuals (HCC n = 1423, ICC n = 410). Multivariable-adjusted hazards ratios (HRs) and 95% confidence intervals (CI) were estimated using proportional hazards regression.

Results: Current smokers at baseline had an increased risk of HCC (hazard ratio (HR) = 1.86, 95% confidence interval (CI): 1.57-2.20) and ICC (HR = 1.47, 95% CI: 1.07-2.02). Among individuals who quit smoking >30 years ago, HCC risk was almost equivalent to never smokers (HR = 1.09, 95% CI: 0.74-1.61). Compared to non-drinkers, heavy alcohol consumption was associated with an 87% increased HCC risk (HR≥7 drinks/day = 1.87, 95% CI: 1.41-2.47) and a 68% increased ICC risk (HR≥5 drinks/day = 1.68, 95% CI: 0.99-2.86). However, light-to-moderate alcohol consumption of <3 drinks/day appeared to be inversely associated with HCC risk (HR>0-<0.5 drinks/day = 0.77, 95% CI: 0.67-0.89; HR>0.5-<1 drinks/day = 0.57, 95% CI: 0.44-0.73; HR1-<3 drinks/day = 0.71, 95% CI: 0.58-0.87), but not ICC.

Conclusions: These findings suggest that, in this relatively healthy population, smoking cessation and light-to-moderate drinking may reduce the risk of HCC.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Cubic spline graph of the multivariate-adjusted HRs (represented by the solid line) and 95% CIs (represented by the dotted lines) for the association between smoking intensity and a HCC and b ICC in the Liver Cancer Pooling Project (knots: 0.5, 10, 15, 25; referent: 0)
Fig. 2
Fig. 2
Cubic spline graph of the multivariate-adjusted HRs (represented by the solid line) and 95% CIs (represented by the dotted lines) for the association between drinks per day of alcohol and a HCC (knots: 1, 3, 5, and 7; referent: 0.25) and b ICC (knots: 1, 3, and 5; referent: 0.25) in the Liver Cancer Pooling Project

Similar articles

  • Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project.
    Petrick JL, Freedman ND, Graubard BI, Sahasrabuddhe VV, Lai GY, Alavanja MC, Beane-Freeman LE, Boggs DA, Buring JE, Chan AT, Chong DQ, Fuchs CS, Gapstur SM, Gaziano JM, Giovannucci EL, Hollenbeck AR, King LY, Koshiol J, Lee IM, Linet MS, Palmer JR, Poynter JN, Purdue MP, Robien K, Schairer C, Sesso HD, Sigurdson AJ, Zeleniuch-Jacquotte A, Wactawski-Wende J, Campbell PT, McGlynn KA. Petrick JL, et al. Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1398-406. doi: 10.1158/1055-9965.EPI-15-0137. Epub 2015 Jun 30. Cancer Epidemiol Biomarkers Prev. 2015. PMID: 26126626 Free PMC article.
  • NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project.
    Petrick JL, Sahasrabuddhe VV, Chan AT, Alavanja MC, Beane-Freeman LE, Buring JE, Chen J, Chong DQ, Freedman ND, Fuchs CS, Gaziano JM, Giovannucci E, Graubard BI, Hollenbeck AR, Hou L, Jacobs EJ, King LY, Koshiol J, Lee IM, Linet MS, Palmer JR, Purdue MP, Rosenberg L, Schairer C, Sesso HD, Sigurdson AJ, Wactawski-Wende J, Zeleniuch-Jacquotte A, Campbell PT, McGlynn KA. Petrick JL, et al. Cancer Prev Res (Phila). 2015 Dec;8(12):1156-62. doi: 10.1158/1940-6207.CAPR-15-0126. Epub 2015 Sep 21. Cancer Prev Res (Phila). 2015. PMID: 26391917 Free PMC article.
  • Abdominal and gluteofemoral size and risk of liver cancer: The liver cancer pooling project.
    Florio AA, Campbell PT, Zhang X, Zeleniuch-Jacquotte A, Wactawski-Wende J, Smith-Warner SA, Sinha R, Simon TG, Sesso HD, Schairer C, Rosenberg L, Rohan TE, Robien K, Renehan AG, Purdue MP, Poynter JN, Palmer JR, Newton CC, Lu Y, Linet MS, Liao LM, Lee IM, Koshiol J, Kitahara CM, Kirsh VA, Hofmann JN, Graubard BI, Giovannucci E, Gaziano JM, Gapstur SM, Freedman ND, Demuth J, Chong DQ, Chan AT, Buring JE, Bradshaw PT, Beane Freeman LE, McGlynn KA, Petrick JL. Florio AA, et al. Int J Cancer. 2020 Aug 1;147(3):675-685. doi: 10.1002/ijc.32760. Epub 2019 Dec 23. Int J Cancer. 2020. PMID: 31677159 Free PMC article.
  • Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies.
    McGee EE, Jackson SS, Petrick JL, Van Dyke AL, Adami HO, Albanes D, Andreotti G, Beane-Freeman LE, Berrington de Gonzalez A, Buring JE, Chan AT, Chen Y, Fraser GE, Freedman ND, Gao YT, Gapstur SM, Gaziano JM, Giles GG, Grant EJ, Grodstein F, Hartge P, Jenab M, Kitahara CM, Knutsen SF, Koh WP, Larsson SC, Lee IM, Liao LM, Luo J, Milne RL, Monroe KR, Neuhouser ML, O'Brien KM, Peters U, Poynter JN, Purdue MP, Robien K, Sandler DP, Sawada N, Schairer C, Sesso HD, Simon TG, Sinha R, Stolzenberg-Solomon R, Tsugane S, Wang R, Weiderpass E, Weinstein SJ, White E, Wolk A, Yuan JM, Zeleniuch-Jacquotte A, Zhang X, Zhu B, McGlynn KA, Campbell PT, Koshiol J. McGee EE, et al. J Natl Cancer Inst. 2019 Dec 1;111(12):1263-1278. doi: 10.1093/jnci/djz103. J Natl Cancer Inst. 2019. PMID: 31127946 Free PMC article. Review.
  • Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis.
    Petrick JL, Thistle JE, Zeleniuch-Jacquotte A, Zhang X, Wactawski-Wende J, Van Dyke AL, Stampfer MJ, Sinha R, Sesso HD, Schairer C, Rosenberg L, Rohan TE, Robien K, Purdue MP, Poynter JN, Palmer JR, Newton CC, Linet MS, Liao LM, Lee IM, Koshiol J, Kitahara CM, Hofmann JN, Graubard BI, Giovannucci E, Gaziano MJ, Gapstur SM, Freedman ND, Chong DQ, Chan AT, Buring JE, Freeman LBE, Campbell PT, McGlynn KA. Petrick JL, et al. Am J Gastroenterol. 2018 Oct;113(10):1494-1505. doi: 10.1038/s41395-018-0207-4. Epub 2018 Sep 3. Am J Gastroenterol. 2018. PMID: 30177781 Free PMC article.

Cited by

References

    1. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Tobacco Smoke and Involuntary Smoking. Lyon, France: IARC; 2004. - PMC - PubMed
    1. Office of the Surgeon General. The Health Consequences of Smoking--50 Years of Progress: A Report Of The Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2014.
    1. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract. Res Clin. Gastroenterol. 2014;28:753–770. doi: 10.1016/j.bpg.2014.08.007. - DOI - PubMed
    1. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin. Liver Dis. 2011;15:223–243. doi: 10.1016/j.cld.2011.03.006. - DOI - PMC - PubMed
    1. Lee YC, et al. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int. J. Epidemiol. 2009;38:1497–1511. doi: 10.1093/ije/dyp280. - DOI - PubMed

Publication types

MeSH terms